<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01767285</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00030001</org_study_id>
    <nct_id>NCT01767285</nct_id>
  </id_info>
  <brief_title>Immediate vs. Delayed Postpartum Etonogestrel Implant</brief_title>
  <official_title>A Randomized Controlled Trial of Immediate Postpartum Etonogestrel Implant Versus Six-week Postpartum Etonogestrel Implant: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are examining if there is a difference in continuation rates of the
      etonogestrel contraceptive implant between women who have the device placed immediately after
      delivery, before leaving the hospital, and women who have the device placed at the routine
      6-week postpartum visit. There will be 60 subjects total, randomized in a 1:1 ratio, for 30
      in each group. All participants will follow-up at the same postpartum clinic 6 weeks after
      delivery. They will then be contacted at 3, 6, and 12 months postpartum and asked to complete
      a brief survey. The investigators hypothesize that continuation rates of Implanon will be
      higher in the immediate postpartum placement arm than in the delayed placement arm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuation Rate</measure>
    <time_frame>1 year</time_frame>
    <description>To identify a difference in continuation rates of Implanon® between women who have the device placed immediately postpartum and women who have the device placed at the 6-week postpartum visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Intercourse</measure>
    <time_frame>6 weeks</time_frame>
    <description>To identify differences in the rates of intercourse prior to the 6-week postpartum visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuation Rate</measure>
    <time_frame>6 months</time_frame>
    <description>To identify a difference in continuation rates of Implanon® at one year between women who have the device placed immediately postpartum and women who have the device placed at the 6-week postpartum visit.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Continuation of Breastfeeding</measure>
    <time_frame>6 months</time_frame>
    <description>To identify differences in continuation of breast-feeding at 6 months between women who have immediate versus delayed (6 weeks) postpartum Implanon® placement.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pregnancy Rate</measure>
    <time_frame>12 months</time_frame>
    <description>To identify differences pregnancy rates between women who have immediate versus delayed (6 weeks) postpartum Implanon® placement.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>12 months</time_frame>
    <description>To identify differences in satisfaction with birth control method between women who have immediate versus delayed (6 weeks) postpartum Implanon® placement.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Continuation Rate of Contraceptive Implant</condition>
  <arm_group>
    <arm_group_label>Immediate Postpartum Etonogestrel Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etonogestrel implant placed in the hospital after delivery, before discharge home.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed postpartum etonogestrel implant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These subjects will have the etonogestrel implant placed at the 6 week postpartum visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etonogestrel implant</intervention_name>
    <description>This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
    <arm_group_label>Immediate Postpartum Etonogestrel Implant</arm_group_label>
    <arm_group_label>Delayed postpartum etonogestrel implant</arm_group_label>
    <other_name>Implanon</other_name>
    <other_name>Nexplanon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1)Age 12-40 years 2)Must deliver at Duke Hospital 3)Must have a working telephone number
        4)No contraindications to receiving this method of contraception, which include: known or
        suspected pregnancy, active liver disease or hepatic tumor, current or past history of
        thrombosis or thromboembolic disorder, undiagnosed abnormal genital bleeding, known or
        suspected breast cancer or history of breast cancer, hypersensitivity to any of the
        components of the device.

        Exclusion Criteria:

          1. Not meeting inclusion criteria

          2. Use of chronic medical therapy that has an adverse interaction with etonogestrel.
             Medications that will be cause for exclusion from the study include:

        1. Non-nucleoside reverse transcriptase inhibitors 2. ritonavir-boosted protease inhibitors
        3. Certain anticonvulsants - phenytoin, carbamazepine, barbiturates, primidone, topiramate,
        oxcarbazepine 4. Rifampin 5. St. John's Wort
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Morse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Hospital Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006 Jun;38(2):90-6.</citation>
    <PMID>16772190</PMID>
  </reference>
  <reference>
    <citation>Espey E, Ogburn T. Long-acting reversible contraceptives: intrauterine devices and the contraceptive implant. Obstet Gynecol. 2011 Mar;117(3):705-19. doi: 10.1097/AOG.0b013e31820ce2f0. Review.</citation>
    <PMID>21343774</PMID>
  </reference>
  <reference>
    <citation>Guazzelli CA, de Queiroz FT, Barbieri M, Torloni MR, de Araujo FF. Etonogestrel implant in postpartum adolescents: bleeding pattern, efficacy and discontinuation rate. Contraception. 2010 Sep;82(3):256-9. doi: 10.1016/j.contraception.2010.02.010. Epub 2010 Mar 29.</citation>
    <PMID>20705154</PMID>
  </reference>
  <reference>
    <citation>Lewis LN, Doherty DA, Hickey M, Skinner SR. Implanon as a contraceptive choice for teenage mothers: a comparison of contraceptive choices, acceptability and repeat pregnancy. Contraception. 2010 May;81(5):421-6. doi: 10.1016/j.contraception.2009.12.006. Epub 2010 Jan 15.</citation>
    <PMID>20399949</PMID>
  </reference>
  <reference>
    <citation>Croxatto HB, Urbancsek J, Massai R, Coelingh Bennink H, van Beek A. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Hum Reprod. 1999 Apr;14(4):976-81.</citation>
    <PMID>10221230</PMID>
  </reference>
  <reference>
    <citation>Funk S, Miller MM, Mishell DR Jr, Archer DF, Poindexter A, Schmidt J, Zampaglione E; Implanon US Study Group. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception. 2005 May;71(5):319-26.</citation>
    <PMID>15854630</PMID>
  </reference>
  <reference>
    <citation>Brito MB, Ferriani RA, Quintana SM, Yazlle ME, Silva de Sá MF, Vieira CS. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. Contraception. 2009 Dec;80(6):519-26. doi: 10.1016/j.contraception.2009.05.124. Epub 2009 Jul 10.</citation>
    <PMID>19913145</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2013</study_first_posted>
  <results_first_submitted>March 30, 2016</results_first_submitted>
  <results_first_submitted_qc>October 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2016</results_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Etonogestrel Implant</keyword>
  <keyword>Implanon</keyword>
  <keyword>Nexplanon</keyword>
  <keyword>Long Acting Reversible Contraception</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>60 participants signed consent. 1 participant was a screen failure. 59 participants were randomized.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Immediate Postpartum Etonogestrel Implant</title>
          <description>Etonogestrel implant placed in the hospital after delivery, before discharge home.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
        </group>
        <group group_id="P2">
          <title>Delayed Postpartum Etonogestrel Implant</title>
          <description>These subjects will have the etonogestrel implant placed at the 6 week postpartum visit.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Immediate Postpartum Etonogestrel Implant</title>
          <description>Etonogestrel implant placed in the hospital after delivery, before discharge home.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
        </group>
        <group group_id="B2">
          <title>Delayed Postpartum Etonogestrel Implant</title>
          <description>These subjects will have the etonogestrel implant placed at the 6 week postpartum visit.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Continuation Rate</title>
        <description>To identify a difference in continuation rates of Implanon® between women who have the device placed immediately postpartum and women who have the device placed at the 6-week postpartum visit.</description>
        <time_frame>1 year</time_frame>
        <population>Participants who completed the 1 year phone visit were included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Immediate Postpartum Etonogestrel Implant</title>
            <description>Etonogestrel implant placed in the hospital after delivery, before discharge home.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Postpartum Etonogestrel Implant</title>
            <description>These subjects will have the etonogestrel implant placed at the 6 week postpartum visit.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Continuation Rate</title>
          <description>To identify a difference in continuation rates of Implanon® between women who have the device placed immediately postpartum and women who have the device placed at the 6-week postpartum visit.</description>
          <population>Participants who completed the 1 year phone visit were included in analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Intercourse</title>
        <description>To identify differences in the rates of intercourse prior to the 6-week postpartum visit.</description>
        <time_frame>6 weeks</time_frame>
        <population>Participants who completed the 6 week assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Immediate Postpartum Etonogestrel Implant</title>
            <description>Etonogestrel implant placed in the hospital after delivery, before discharge home.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Postpartum Etonogestrel Implant</title>
            <description>These subjects will have the etonogestrel implant placed at the 6 week postpartum visit.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Intercourse</title>
          <description>To identify differences in the rates of intercourse prior to the 6-week postpartum visit.</description>
          <population>Participants who completed the 6 week assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Continuation Rate</title>
        <description>To identify a difference in continuation rates of Implanon® at one year between women who have the device placed immediately postpartum and women who have the device placed at the 6-week postpartum visit.</description>
        <time_frame>6 months</time_frame>
        <population>Participants who completed the 6 month assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Immediate Postpartum Etonogestrel Implant</title>
            <description>Etonogestrel implant placed in the hospital after delivery, before discharge home.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Postpartum Etonogestrel Implant</title>
            <description>These subjects will have the etonogestrel implant placed at the 6 week postpartum visit.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Continuation Rate</title>
          <description>To identify a difference in continuation rates of Implanon® at one year between women who have the device placed immediately postpartum and women who have the device placed at the 6-week postpartum visit.</description>
          <population>Participants who completed the 6 month assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Continuation of Breastfeeding</title>
        <description>To identify differences in continuation of breast-feeding at 6 months between women who have immediate versus delayed (6 weeks) postpartum Implanon® placement.</description>
        <time_frame>6 months</time_frame>
        <population>Participants who completed the 6 month assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Immediate Postpartum Etonogestrel Implant</title>
            <description>Etonogestrel implant placed in the hospital after delivery, before discharge home.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Postpartum Etonogestrel Implant</title>
            <description>These subjects will have the etonogestrel implant placed at the 6 week postpartum visit.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Continuation of Breastfeeding</title>
          <description>To identify differences in continuation of breast-feeding at 6 months between women who have immediate versus delayed (6 weeks) postpartum Implanon® placement.</description>
          <population>Participants who completed the 6 month assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pregnancy Rate</title>
        <description>To identify differences pregnancy rates between women who have immediate versus delayed (6 weeks) postpartum Implanon® placement.</description>
        <time_frame>12 months</time_frame>
        <population>all participants who completed the 12 month follow up visit</population>
        <group_list>
          <group group_id="O1">
            <title>Immediate Postpartum Etonogestrel Implant</title>
            <description>Etonogestrel implant placed in the hospital after delivery, before discharge home.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Postpartum Etonogestrel Implant</title>
            <description>These subjects will have the etonogestrel implant placed at the 6 week postpartum visit.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Pregnancy Rate</title>
          <description>To identify differences pregnancy rates between women who have immediate versus delayed (6 weeks) postpartum Implanon® placement.</description>
          <population>all participants who completed the 12 month follow up visit</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Satisfaction</title>
        <description>To identify differences in satisfaction with birth control method between women who have immediate versus delayed (6 weeks) postpartum Implanon® placement.</description>
        <time_frame>12 months</time_frame>
        <population>Participants who completed the 12 month patient satisfaction assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Immediate Postpartum Etonogestrel Implant</title>
            <description>Etonogestrel implant placed in the hospital after delivery, before discharge home.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
          </group>
          <group group_id="O2">
            <title>Delayed Postpartum Etonogestrel Implant</title>
            <description>These subjects will have the etonogestrel implant placed at the 6 week postpartum visit.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>To identify differences in satisfaction with birth control method between women who have immediate versus delayed (6 weeks) postpartum Implanon® placement.</description>
          <population>Participants who completed the 12 month patient satisfaction assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Immediate Postpartum Etonogestrel Implant</title>
          <description>Etonogestrel implant placed in the hospital after delivery, before discharge home.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
        </group>
        <group group_id="E2">
          <title>Delayed Postpartum Etonogestrel Implant</title>
          <description>These subjects will have the etonogestrel implant placed at the 6 week postpartum visit.
Etonogestrel implant: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Beverly Gray</name_or_title>
      <organization>Duke University</organization>
      <phone>919-684-8111</phone>
      <email>beverly.gray@dm.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

